Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy

Naomi Hayashi,1 Yasuyoshi Sato,1 Yu Fujiwara,1,2 Naoki Fukuda,1 Xiaofei Wang,1 Kenji Nakano,1 Testuya Urasaki,1 Akihiro Ohmoto,1 Makiko Ono,1 Junichi Tomomatsu,1 Yukiko Sato,3 Hiroki Mitani,4 Takashi Toshiyasu,5 Shunji Takahashi1 1Department of Medical Oncology, The Cancer Institute Hospital of Japa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hayashi N, Sato Y, Fujiwara Y, Fukuda N, Wang X, Nakano K, Urasaki T, Ohmoto A, Ono M, Tomomatsu J, Mitani H, Toshiyasu T, Takahashi S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	head and neck cancer squamous cell carcinoma of head and neck sarcopenia cachexia muscle skeletal chemoradiotherapy prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f6ba371db3634bd18c1e7f974d8c232e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6ba371db3634bd18c1e7f974d8c232e
record_format	dspace
spelling	oai:doaj.org-article:f6ba371db3634bd18c1e7f974d8c232e2021-11-09T18:40:35ZClinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy1179-1322https://doaj.org/article/f6ba371db3634bd18c1e7f974d8c232e2021-11-01T00:00:00Zhttps://www.dovepress.com/clinical-impact-of-cachexia-in-head-and-neck-cancer-patients-who-recei-peer-reviewed-fulltext-article-CMARhttps://doaj.org/toc/1179-1322Naomi Hayashi,1 Yasuyoshi Sato,1 Yu Fujiwara,1,2 Naoki Fukuda,1 Xiaofei Wang,1 Kenji Nakano,1 Testuya Urasaki,1 Akihiro Ohmoto,1 Makiko Ono,1 Junichi Tomomatsu,1 Yukiko Sato,3 Hiroki Mitani,4 Takashi Toshiyasu,5 Shunji Takahashi1 1Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 2Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York City, NY, USA; 3Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 4Head and Neck Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 5Radiation Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JapanCorrespondence: Yasuyoshi SatoThe Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550, JapanTel +8135200111Fax +81335200141Email yasuyoshi.sato@jfcr.or.jpPurpose: There have been few reports on the evaluation of cancer cachexia based on skeletal muscle mass index (SMI) in patients with head and neck cancer.Patients and Methods: One hundred and ninety-two head and neck cancer patients were enrolled. In definitive and adjuvant chemoradiotherapy settings, clinical outcomes were compared between cachexia and non-cachexia patients.Results: Forty patients were diagnosed with cachexia (20.8%). In the definitive setting, overall survival (OS) was significantly shorter in the cachexia group (3-year OS: 50.0% vs 88.5%; p < 0.01), and multivariate analysis identified UICC stage IV, baseline albumin of < 4 and cachexia as poor prognostic factors. However, cachexia was not significant in the adjuvant setting.Conclusion: Cancer cachexia was negatively associated with prognosis in patients with HNC who received definitive chemoradiotherapy. Nutritional intervention during chemoradiotherapy may improve survival in these patients.Keywords: head and neck cancer, squamous cell carcinoma of head and neck, sarcopenia, cachexia, muscle, skeletal, chemoradiotherapy, prognosisHayashi NSato YFujiwara YFukuda NWang XNakano KUrasaki TOhmoto AOno MTomomatsu JSato YMitani HToshiyasu TTakahashi SDove Medical Pressarticlehead and neck cancersquamous cell carcinoma of head and necksarcopeniacachexiamuscleskeletalchemoradiotherapyprognosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Management and Research, Vol Volume 13, Pp 8377-8385 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	head and neck cancer squamous cell carcinoma of head and neck sarcopenia cachexia muscle skeletal chemoradiotherapy prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	head and neck cancer squamous cell carcinoma of head and neck sarcopenia cachexia muscle skeletal chemoradiotherapy prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hayashi N Sato Y Fujiwara Y Fukuda N Wang X Nakano K Urasaki T Ohmoto A Ono M Tomomatsu J Sato Y Mitani H Toshiyasu T Takahashi S Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
description	Naomi Hayashi,1 Yasuyoshi Sato,1 Yu Fujiwara,1,2 Naoki Fukuda,1 Xiaofei Wang,1 Kenji Nakano,1 Testuya Urasaki,1 Akihiro Ohmoto,1 Makiko Ono,1 Junichi Tomomatsu,1 Yukiko Sato,3 Hiroki Mitani,4 Takashi Toshiyasu,5 Shunji Takahashi1 1Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 2Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York City, NY, USA; 3Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 4Head and Neck Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 5Radiation Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JapanCorrespondence: Yasuyoshi SatoThe Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550, JapanTel +8135200111Fax +81335200141Email yasuyoshi.sato@jfcr.or.jpPurpose: There have been few reports on the evaluation of cancer cachexia based on skeletal muscle mass index (SMI) in patients with head and neck cancer.Patients and Methods: One hundred and ninety-two head and neck cancer patients were enrolled. In definitive and adjuvant chemoradiotherapy settings, clinical outcomes were compared between cachexia and non-cachexia patients.Results: Forty patients were diagnosed with cachexia (20.8%). In the definitive setting, overall survival (OS) was significantly shorter in the cachexia group (3-year OS: 50.0% vs 88.5%; p < 0.01), and multivariate analysis identified UICC stage IV, baseline albumin of < 4 and cachexia as poor prognostic factors. However, cachexia was not significant in the adjuvant setting.Conclusion: Cancer cachexia was negatively associated with prognosis in patients with HNC who received definitive chemoradiotherapy. Nutritional intervention during chemoradiotherapy may improve survival in these patients.Keywords: head and neck cancer, squamous cell carcinoma of head and neck, sarcopenia, cachexia, muscle, skeletal, chemoradiotherapy, prognosis
format	article
author	Hayashi N Sato Y Fujiwara Y Fukuda N Wang X Nakano K Urasaki T Ohmoto A Ono M Tomomatsu J Sato Y Mitani H Toshiyasu T Takahashi S
author_facet	Hayashi N Sato Y Fujiwara Y Fukuda N Wang X Nakano K Urasaki T Ohmoto A Ono M Tomomatsu J Sato Y Mitani H Toshiyasu T Takahashi S
author_sort	Hayashi N
title	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
title_short	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
title_full	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
title_fullStr	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
title_full_unstemmed	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
title_sort	clinical impact of cachexia in head and neck cancer patients who received chemoradiotherapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f6ba371db3634bd18c1e7f974d8c232e
work_keys_str_mv	AT hayashin clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT satoy clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT fujiwaray clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT fukudan clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT wangx clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT nakanok clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT urasakit clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT ohmotoa clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT onom clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT tomomatsuj clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT satoy clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT mitanih clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT toshiyasut clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy AT takahashis clinicalimpactofcachexiainheadandneckcancerpatientswhoreceivedchemoradiotherapy
_version_	1718440897559920640

Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy

Ejemplares similares